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bstract
Background. Previous studies have shown similar effects of rabeprazole and omeprazole, when used at the same dose in the treatment of
eflux oesophagitis. However, such studies have been conducted as superiority studies but interpreted as equivalence ones.
Aim. To properly assess the comparative efficacy of rabeprazole and omeprazole in inducing complete endoscopic healing and symptom
elief in patients with reflux oesophagitis.
Methods. Patients (n= 560) with Savary–Miller grade I–III reflux oesophagitis were randomised in a double-blind, double-dummy fashion
o rabeprazole or omeprazole 20 mg once daily for 4–8 weeks. Then, patients endoscopically healed and symptomatically relieved were openly
aintained with rabeprazole 10 mg or 2× 10 mg once daily (in the event of clinical and/or endoscopic relapse) for a maximum of 48 weeks.
Results. After 4–8 weeks of treatment, healing (primary end-point) was observed in 228/233 (97.9%) patients in the rabeprazole group
nd in 231/237 (97.5%) in the omeprazole one (equivalence effect demonstrated by p< 0.0001 at Blackwelder test and an upper confidence
imit at 97.5% of 0.023). However, rabeprazole was faster in inducing heartburn relief than omeprazole (2.8± 0.2 versus 4.7± 0.5 days of
herapy to reach the first day with satisfactory heartburn relief, p= 0.0045 at log-rank test). In the maintenance phase, 15.2% of patients had
n endoscopic and/or clinical relapse.
Conclusion. Rabeprazole is equivalent to omeprazole in healing reflux oesophagitis, but shows a faster activity on reflux symptoms in the
arly treatment phase.
2005 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
Gastro-oesophageal reflux disease (GORD) is a highly
prevalent gastrointestinal disorder and is one of the most
common gastroenterological illnesses encountered in clinical
590-8658/$30 © 2005 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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practice, affecting all age groups, particularly older adults
[1]. As an example, a cross-sectional survey conducted in
the USA in 1976 among healthy adults found that 7% of
individuals experienced heartburn daily, 14% weekly and
15% monthly [2]. More recently, two surveys conducted in
the USA and the UK show that approximately 20% of the
general adult population experiences heartburn at least once
weekly [3,4].
GORD has a significant negative impact on health-related
quality of life (HRQoL) [5,6] comparable to that induced by
clinically relevant diseases such as angina pectoris or mild
heart failure [7]. Interestingly, HRQoL impairment due to
GORD is more related to the severity of symptoms than to
the presence or absence of mucosal lesions, and can be fully
restored with effective therapy [8]. Finally, the disease has a
tendency to persist for years or even decades [9], i.e., it is not
a self-limiting one and a maintenance therapy is needed in
the majority of patients.
The goals of treatment are, therefore, two-fold: to relieve
symptoms and heal mucosal lesions, if present, and to prevent
relapses, which occur almost inevitably after acute treatment
discontinuation [8]. Proton pump inhibitors (PPIs) are at
present the best therapeutic choice for achieving all these
goals; on one hand, they have been shown to be superior to
H2-receptor antagonists in acutely healing erosive/ulcerative
lesions and relieving symptoms [10,11], on the other hand,
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and, in case of symptomatic/endoscopic relapse, returning to
full dose until the end of the year; (ii) to evaluate the time
of action of rabeprazole 20 mg once daily and omeprazole
20 mg once daily in inducing symptom relief in the curative
phase of the trial; (iii) to evaluate the impact of curative treat-
ments and initial grading of oesophagitis on the outcome of
the maintenance treatment.
2. Materials and methods
2.1. Study design
The study was conducted at 71 Italian investigational sites
(see Appendix). It was divided into two phases; after giving
their written informed consent, patients with moderate to very
severe reflux symptoms and endoscopic evidence of mild
to severe oesophagitis entered a curative phase where they
were randomised in a double-blind, double-dummy fashion,
to either rabeprazole 20 mg or omeprazole 20 mg daily for
at least 4 weeks. During this phase, patients were invited to
take before breakfast, in a double-blind, double-dummy way,
one tablet of rabeprazole 20 mg + one omeprazole-placebo
capsule once daily or vice versa, i.e., one capsule of omepra-
zole 20 mg + one rabeprazole-placebo tablet. Randomisation
to treatments was done centrally by means of a randomisa-
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daintenance treatment with such drugs appear to be an effec-
ive and appropriate form of therapy in many GORD patients
nd it is recommended in current practice guidelines [1].
Rabeprazole is a recently introduced PPI, shown to be
ighly effective. When compared with placebo or raniti-
ine, rabeprazole achieved significantly higher healing rates
nd symptom relief [12,13]. Moreover, previous studies have
lready shown the similar efficacy with omeprazole, in both
hort- and long-term therapy of GORD [14–17]. However,
hese studies are potentially biased since they have been
riginally planned as superiority-studies but interpreted a
osteriori as equivalency ones as long as they were not able
o detect any differences between the two PPIs. This way
f demonstrating absence of therapeutical differences has
ecently been claimed not only to be poorly supported by the
vidence, but also inherently wrong from a statistical point
f view [18]. As a matter of fact, trials to assess equiva-
ence need rigorous methods, such as appropriate statistical
esign and tests [19]. The primary aim of the present study
as to assess, by an ad hoc design and analysis, the equiva-
ent comparative efficacy of rabeprazole and omeprazole at
tandard doses (20 mg once daily) in inducing complete heal-
ng of mucosal damage in patients with reflux oesophagitis
f grades I–III according to the Savary–Miller classification
nd reflux symptoms of intensity ≥2 on a Likert scale from
to 5.
Secondary aims were (i) to assess the efficacy of low-dose
10 mg once daily) rabeprazole in maintaining symptomatic
nd endoscopic remission for 1 year with a flexible thera-
eutic approach, i.e., treating healed patients with a low doseion list. Those patients who were not endoscopically cured
nd not symptomatically improved after 1 month received
he curative treatment for an additional 4 weeks. Control
isits were repeated every 2 weeks. At the end of the first
hase, patients with improvement in reflux symptoms and
omplete endoscopic healing were admitted to an open, long-
erm maintenance period with a low dose (10 mg once daily)
f rabeprazole for a maximum duration of 48 weeks. In this
hase, patients received in an open way one tablet of rabepra-
ole 10 mg once daily in the morning. The dosage was to
e doubled to 2× 10 mg rabeprazole tablets once daily until
he end of the study in case of clinical and/or endoscopic
elapse.
During this phase, control visits were performed every 12
eeks, but extra visits were foreseen whenever the patients
equired them for efficacy and tolerability problems.
The study was conducted in accordance with the Declara-
ion of Helsinki and its subsequent revisions and with Good
linical Practice (GCP). The study protocol was approved by
he appropriate Independent Ethics Committees.
.2. Patients
Main inclusion criteria for the curative phase were (i) male
nd/or female outpatients aged ≥18 years; (ii) presence of
esophagitis of grades I–III (according to the four-degree
avary–Miller classification) at an endoscopy during the last
days prior to inclusion in the trial; (iii) a minimum heartburn
core of 2 (see assessment) for both frequency and intensity at
aytime and/or nighttime; (iv) a history of at least 3 months
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of oesophagitis-like symptoms and heartburn for at least 3
days in each of the 2 weeks prior to inclusion.
Inclusion criteria for the maintenance phase were (i) com-
plete healing of oesophagitis confirmed by endoscopy at the
end of the curative phase; (ii) relief of reflux symptoms,
defined as a score ≤1 for both frequency and intensity of
daytime and nighttime heartburn.
Main exclusion criteria were (i) oesophagitis of infectious
origin or caused by exogenous acid or alkaline substances;
(ii) grade IV oesophagitis according to Savary–Miller; (iii)
Zollinger–Ellison syndrome; (iv) presence of an active gas-
troduodenal ulcer or previous oesophageal, gastric or bil-
iary surgery (including vagotomy); (v) primary oesophageal
motility disorders; (vi) recent treatment with PPIs (within 2
weeks) and previous (for more than five consecutive days
in the 2 weeks prior to trial entry) or concomitant ther-
apy with H2-receptor antagonists, prokinetic agents, anti-
cholinergics or mucosal protective agents; (vii) pregnancy or
breast-feeding female; (viii) severe liver and/or renal disease,
end-stage heart or lung disease; (ix) cancer or HIV infection;
(x) daily use of NSAIDs; alcoholism or drug abuse.
2.3. Assessments
2.3.1. Endoscopy
An endoscopy was performed at the baseline visit, after
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Frequency: 0 = absent; 1 = occasional (≤2 days/week); 2 =
frequent (3–4 days/week); 3 = very frequent (5–6 days/week);
4 = every day (7 days/week).
Patients were asked to keep a daily diary to record the
intensity of reflux symptoms throughout the curative phase
with the same scoring system described above.
2.3.3. Overall assessment and global evaluation
At each visit of the trial after the baseline evaluation,
patients were also queried on their condition (reflux symp-
toms and general well-being), rating it on the following five-
point Likert scale: 0 (very good), 1 (good), 2 (fair), 3 (poor)
and 4 (very poor).
Data were also collected on the use of rescue (antacid)
medication and adverse events.
2.4. Statistical analysis
The primary endpoint of the study was to confirm the
equivalence of the two drugs on the endoscopic healing rate at
the end of the curative phase, i.e., after 4–8 weeks of double-
blind treatment in the per-protocol patient sample.
The sample size was calculated assuming a response rate
(endoscopic cure of oesophagitis) with rabeprazole 20 mg
once daily or omeprazole 20 mg once daily of 88%; under
these circumstances, a number of 222 patients in each treat-
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pweeks of double-blind treatment and after 8 weeks if no
ndoscopic healing was seen at 4 weeks. Moreover, patients
ad a final evaluation at 48 weeks of the maintenance phase,
ut an additional endoscopy could be performed whenever
he investigator judged it necessary.
The scoring according to the Savary–Miller scale was as
ollows: grade I, one or more non-confluent erosions; grade II,
onfluent mucosal erosions which did not involve the entire
ircumference of the oesophageal lumen; grade III, conflu-
nt erosions which involved the entire circumference of the
esophageal lumen; grade IV, ulcer, stricture, short oesoph-
gus and/or Barrett’s oesophagus.
Helicobacter pylori status was assessed by histology (at
east two biopsies from the antrum and two biopsies from the
ody of the stomach) at the time of baseline endoscopy.
.3.2. Reﬂux symptoms
Reflux symptoms such as regurgitation, daytime and
ighttime heartburn and other associated complaints (epi-
astric pain/burning, dysphagia, nausea, nocturnal coughing
nd nocturnal wheezing) were assessed by the investigator at
aseline and at every visit until the end of the study, using
he following scoring system and referring to the week prior
o the visit.
Intensity: 0 = absent; 1 = mild (present, but causing little
r no discomfort); 2 = moderate (annoying, but not interfer-
ng with usual activities or with sleep); 3 = severe (causing
arked discomfort and some interference with usual activ-
ties or with sleep); 4 = terrible (disabling, considerable
nterference with usual activities or sleep).ent group were required to be able to detect a 10% differ-
nce between treatments with an alpha value of 2.5% and a
ower of 90%. Considering a 10% rate of incomplete, miss-
ng or drop-out data, it was estimated to have a sample of 504
atients.
The Blackwelder test was used to prove equivalence of
abeprazole versus omeprazole with an allowable clinical
ifference of 10%. According to this test, the equivalence
etween two drugs is shown by a p-value≤0.05 and the upper
onfidence limit, calculated at 97.5%, should be included in
he above allowable clinical difference of 10% (range 0–0.1).
hus, contrary to the superiority trials, where a p-value≤0.05
s synonymous with proven statistical difference between
wo drugs, in equivalency ones such as ours, a p-value of
Blackwelder test ≤0.05 means statistically proven equiva-
ence [20].
Secondary endpoints were (1) time to onset of relief of
eartburn (intensity ≤1) and (2) time to complete relief of
eartburn (intensity = 0) in the curative phase, during both
aytime and nighttime together or separately, respectively;
3) percentage of patients with satisfactory relief of heartburn
daytime and nighttime intensity ≤1) and (4) percentage
f patients with complete relief of heartburn (daytime
nd nighttime intensity = 0) in each day of the first 3 and
days of the curative phase, during both daytime and
ighttime together or separately, respectively; (5) time to
linical/endoscopic relapse during the maintenance phase;
nd (6) overall assessment and global evaluation. For
nalysis of secondary endpoints, the intention-to-treat (ITT)
opulation was considered. However, the occurrence of the
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endoscopic/clinical relapse in the maintenance phase was
evaluated with a per-protocol analysis of those patients who
completed the trial and for whom it was possible to collect
the efficacy parameters.
Time to relief of heartburn and time to clinical and/or
endoscopic relapse were evaluated by means of log-rank test.
The percentage of patients with satisfactory/complete relief
of heartburn, the overall assessment and the global evalua-
tion were analysed by means of Cochran–Mantel–Haenszel
statistics.
Adverse events were analysed in the safety sample, which
included all randomised patients who received at least one
dose of the study medication.
3. Results
3.1. Patients
Overall, 560 patients were included in the curative phase
(an average of 7.9 patients enrolled per centre, ranging
between a minimum of one and a maximum contribution
of 19 patients) and were randomised, 283 in the rabepra-
zole group and 277 in the omeprazole group. Of the enrolled
patients, 513 completed the first phase and 47 patients (25
in the rabeprazole group and 22 in the omeprazole group)
dropped out due to different reasons. As far as the mainte-
nance phase is concerned, 502 patients were admitted, 253
from the rabeprazole group and 249 from the omeprazole
group: out of these patients, 425 completed the maintenance
study, while 77 patients (44 from the rabeprazole group and
33 from the omeprazole group) left the study prematurely.
The flow of patients through the two phases of the study,
according to the CONSORT guidelines, is shown in Fig. 1.
Patient demographic and baseline characteristics were
well matched amongst the two treatment groups (Table 1).
3.2. Efﬁcacy curative phase
3.2.1. Endoscopic healing
After 4 weeks of treatment, 212/233 patients (91.0%) in
the rabeprazole group and 213/237 (89.9%) in the omeprazole
group were completely healed (p< 0.0001 at Blackwelder’s
test and an upper confidence limit at 97.5% of 0.042).Fig. 1. Randomisation protocol and patient disposition.
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Table 1
Baseline demographic and clinical characteristics of patients (safety patients, n= 549)
Rabeprazole (N= 277) Omeprazole (N= 272)
Gender (n, %)
Male 190 (68.6%) 184 (67.7%)
Female 87 (31.4%) 88 (32.3%)
Age (years), mean (±S.D.) 47.7 (±14.2) 47.1 (±14.9)
Body mass index (BMI) (kg/m2), mean (±S.D.) 26.2 (±3.6) 26.6 (±3.8)
Duration of symptoms (months), mean (±S.D.) 51.5 (±59.0) 56.6 (±67.2)
Patients with a first episode of oesophagitis (n, %) 186 (67.2%) 200 (73.5%)
Oesophagitis grade (n, %)
Grade 0 3 (1.1%) 3 (1.1%)
Grade I 188 (67.9%) 192 (70.6%)
Grade II 71 (25.6%) 62 (22.8%)
Grade III 15 (5.4%) 15 (5.5%)
Regurgitation (n, %) 231 (83.4%) 219 (80.5%)
Heartburn (n, %)
During daytime 272 (98.2%) 265 (97.4%)
During nighttime 206 (74.4%) 205 (75.4%)
Epigastric pain (n, %) 196 (70.8%) 190 (69.9%)
Endoscopic lesions after 4 more weeks of treatment were
still evident in two out of 21 patients (both grade I) in the
rabeprazole group and in five out of 24 patients (four grade
I and one grade II) in the omeprazole group, bringing the
success rate at endpoint to 97.9% (228 of 233) in the rabepra-
zole group and 97.5% (231 of 237) in the omeprazole group
(p< 0.0001 at Blackwelder’s test and an upper confidence
limit at 97.5% of 0.023) (Fig. 2). The healing rate at endpoint
in the two groups, according to the initial grade of oesophagi-
tis, is presented in Fig. 3. Again, no differences can be seen
between the two groups, even if a numerical trend is present
in favour of rabeprazole in the most severe grade.
3.2.2. Reﬂux symptoms
In the ITT population, the mean time to the first day
with satisfactory heartburn relief was significantly shorter
for the rabeprazole group patients (n= 271) (2.8± 0.2 days,
mean±S.E.M.) than with the omeprazole group patients
(n= 271) (4.7± 0.5 days) (p= 0.0045 at log-rank test).
Mean time to complete heartburn relief was similar: 7.2
days in the rabeprazole group (n= 271) and 8.4 in the omepra-
zole group (n= 271) (p= 0.1342 at log-rank test).
Fig. 2. Healing rates at 4 weeks and at endpoint according to treatment (per-
protocol patients) (rabeprazole n= 233, omeprazole n= 237). Please note
that p< 0.0001 at Blackwelder’s test means that the equivalence between the
two drugs is statistically significant (cf. Section 2.4 in the text).
Rabeprazole also showed a more sustained activity com-
pared with omeprazole in controlling reflux symptoms in
each day of the first week of the curative phase: 32.2% (79 of
245) of patients in the rabeprazole group reported complete
F (per-protocol patients) (rabeprazole n= 233, omeprazole n= 237). Please note that
p drugs is statistically significant (cf. Section 2.4 in the text).ig. 3. Healing rates according to initial oesophagitis grade and treatment
< 0.0001 at Blackwelder’s test means that the equivalence between the two
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Fig. 4. Percentages of patients with complete heartburn relief (daytime and
nighttime) in each day of the first week of treatment (ITT patients) (rabepra-
zole n=245, omeprazole n= 243).
heartburn relief during both daytime and nighttime compared
with 18.9% (46 of 243) in the omeprazole group (p= 0.0010,
at Cochran–Mantel–Haenszel test) (Fig. 4), whereas the per-
centage of patients with satisfactory heartburn relief during
the same period was 50.6% (124 of 245) and 41.2% (100 of
243), respectively (p= 0.0585, at Cochran–Mantel–Haenszel
test).
Interestingly, the effect of both treatments was more pro-
nounced on the nighttime symptoms than on the daytime
ones. Complete relief of nighttime heartburn was observed,
after 7 days of therapy in 53.9% (132 of 245) patients in
the rabeprazole group and in 42.8% (104 of 243) patients
in the omeprazole group (p= 0.0195), but only in 83 out of
245 (33.9%) and 66 out of 243 (27.2%), respectively, dur-
ing the daytime (p= 0.1224) (Fig. 5). The same trend was
observed when analysing the first 3 days of treatment; day-
time and nighttime heartburn were completely relieved in
37.1% (91 of 245) of rabeprazole group versus 23.1% (56 of
243) of omeprazole one (p= 0.0008). Again, the effect was
more evident for nighttime symptom, 60.0% (147 of 245)
versus 48.2% (117 of 243) (p= 0.0143).
3.2.3. Overall assessment and global evaluation
Patients’ assessment changed similarly for the two groups
from baseline visit to endpoint visit. The percentage of
patients scoring their overall assessment for reflux symp-
toms as very good or good increased from 7.0 (rabeprazole
group) and 5.5% (omeprazole group) to 90.0 and 90.7%,
respectively, at the end of the acute phase. As far as gen-
eral well-being is concerned, the figures were slightly lower
at the end of the curative phase, changing from 41.7 (rabepra-
zole group) and 43.5% (omeprazole group) at the baseline to
89.3 and 86.3% at the end of this phase.
3.2.4. Antacid consumption
Ten percent of patients in the rabeprazole group and 13.6%
in the omeprazole group reported use of antacids at the first
visit after the baseline. This percentage decreased to less than
7% in both groups at the endpoint. The data were not statis-
tically different.
3.2.5. Efﬁcacy maintenance phase
In the ITT sample an endoscopic relapse was observed in
44 out of 422 valuable patients (10.4%) for this parameter;
interestingly, in all the cases, endoscopic relapse was fully
asymptomatic. A clinical relapse occurred in 39 out of 475
valuable patients (8.2%) for this parameter; grouping together
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(ig. 5. Percentages of patients with complete heartburn (nighttime left panel
rabeprazole n= 245, omeprazole n= 243).hose who had endoscopic and/or clinical relapse brought
he total up to 15.2% (n= 73/480) of patients. The time to
ccurrence was 11.1± 2.6 months for endoscopic relapse,
.7± 4.4 for clinical relapse and 9.5± 3.9 for endoscopic
nd/or clinical relapse.
There was no statistically significant influence on relapse
t the log-rank test by using as covariate initial grading and/or
urative treatment, age, gender or BMI.
The percentage of patients that gave a favourable judge-
ent (very good + good) of the overall assessment decreased
n relation to the time to the clinical/endoscopic relapse,
rom 88.6% at 12 weeks to 75.9% at 48 weeks for reflux
e right panel) relief in each day of the first week of treatment (ITT patients)
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symptoms, and from 87.7 to 76.7% for general well-being,
respectively.
Antacid consumption throughout the maintenance phase
was reported on average by less than 5% of patients.
Finally, in 32 out of 38 per-protocol patients showing
an endoscopic relapse, the oesophagitis was found at the
final examination in the complete absence of any preceding
symptom. In six out of 38 patients, who relapsed during the
maintenance phase, a double dose of rabeprazole was able to
induce endoscopic healing in half of them within 4–8 weeks.
With regard to symptom response, only 14 out of 395 per-
protocol patients, who completed the trial, still complained
of relevant symptoms (defined as frequency and intensity of
daytime and nighttime heartburn ≥2).
3.2.6. H. pylori status
No effect was observed as far as the influence of the H.
pylori status at baseline on the primary efficacy variable is
concerned. Grouping together the patients of the two treat-
ment arms, at the end of the curative phase healing occurred
in 168 out of 171 (98.2%)H. pylori +ve subjects as compared
to 276 out of 284 (97.2%) H. pylori−ve patients, (odds ratio
1.6232; CI 0.4247–6.2033), whereas reflux symptoms relief
(defined as frequency and intensity of daytime and nighttime
heartburn ≤1) was reported in 167 out of 171 (97.7%) H.
pylori +ve subjects as compared to 276 out of 284 (97.2%)
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(1.2%), diarrhoea (1.2%), sciatalgia (1.4%) and abdominal
pain (1.2%).
4. Discussion
This study confirms the overall equivalence of the two
treatments, rabeprazole and omeprazole, on acute healing
of reflux oesophagitis by adopting a statistically appropriate
method; at the same time, the clinical results underline the
faster and more sustained activity of rabeprazole on reflux
symptoms in the early treatment phase.
Rabeprazole has already been shown to be equivalent to
omeprazole, when used at the same dose (20 mg daily), in
inducing healing of endoscopic oesophagitis [14,15]. More-
over, when compared with double dose of omeprazole (40 mg
daily), rabeprazole at the standard 20 mg daily showed to
be equivalent to the former in inducing endoscopic healing
at 4–8 weeks and in relieving heartburn [16]. These stud-
ies, however, may be criticised because they are in essence
superiority studies, but as they fail to show any significant
difference, they are a posteriori interpreted as if they would
have been planned and executed as equivalence ones.
We planned already from the design (calculation of sample
size, choice of statistical tests) to perform our study as a
true equivalence one [19]. By doing so, and in particular by
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b. pylori−ve patients (odds ratio 1.2101, CI 0.3589–4.0806).
In the maintenance phase, a clinical and/or endoscopic
elapse occurred in 15 of 144 (10.4%) H. pylori +ve subjects
s compared to 37 of 242 (15.3%) H. pylori −ve patients
odds ratio 1.5522, CI 0.8192–2.9410).
.2.7. Analysis of adverse events
Two percent of patients were withdrawn from the study
ue to adverse effects during the acute phase and 1.8% dur-
ng the maintenance period. Overall, the percentage rate of
dverse events remained stable or even decreased from the
cute to the maintenance phase.
The most frequent adverse events were recorded on the
I system. There was no significant difference between
reatment groups in single adverse events occurring dur-
ng the acute phase, with the sole exception of headache;
t was reported more frequently in the omeprazole than in
he rabeprazole group (4.8% n= 13/17 versus 1.4% n= 4/17,
= 0.0241, at the Chi-square test). The treatment-related
dverse events were similar to those already known from
nternational literature and product characteristic summaries
or test and reference drugs. Serious adverse effects in the
urative phase occurred in only three patients, all belonging
o the omeprazole group, but were not related to omeprazole
herapy in itself in all instances.
Concerning the maintenance phase, severe adverse effects
ccurred in 12 patients. There was no adverse event with
n incidence greater than 2%, and only few events with an
ncidence greater or equal to 1%, such as flu (1.8%), fever
1.0%), hypertension (1.0%), headache (1.8%), dyspepsiadopting the Blackwelder test for the equivalence, we can
ruly say that healing rates observed with the two drugs are
quivalent, either at 4 weeks (91.0% healed with rabeprazole
ersus 89.9% with omeprazole) or at the endpoint (97.9%
ersus 97.5%, respectively). The reason for this considerably
igh healing rate in either group is probably to be accounted
y the high proportion of patients (roughly two-thirds) with
rade 1 oesophagitis at baseline, which is known to show the
astest healing rate. Even if the results of endoscopic cure
re analysed by initial grade, the data show equivalent results
etween rabeprazole- and omeprazole-treated patients.
Interestingly, in the above-cited study comparing standard
abeprazole versus double dose of omeprazole [16], signif-
cantly fewer patients reported severe heartburn during the
rst 3 days of treatment in the rabeprazole group, thus sug-
esting a faster onset of antisecretory action with this drug
han with omeprazole.
A faster onset of action of rabeprazole in comparison
o other PPIs was demonstrated recently by the study of
antoflickova et al. [21], who performed a double-blind, ran-
omised, cross-over comparison of rabeprazole 20 mg, lan-
oprazole 30 mg, pantoprazole 40 mg and omeprazole 20 mg
nce daily in 18 healthy H. pylori-negative subjects. The
uthors showed that already after 1 day of dosing, intragastric
H and the time with intragastric pH >4 were significantly
reater with rabeprazole than with any other PPI investigated.
This favourable pharmacological characteristic of
abeprazole may be clinically translated into a more rapid
nset of symptom relief. This was the case in a recent study
y Robinson et al. [22] evaluating timing of symptom relief,
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changes in symptom severity, HRQoL and safety of rabepra-
zole therapy in endoscopically confirmed erosive GORD. In
this large community-based study, called the Future of Acid
Suppression Therapy (FAST) trial, rabeprazole was able to
induce substantial symptom relief already on day 1, with
continuous improvement over the first week.
In our trial, the mean time to onset and complete relief of
symptoms, as assessed by survival analysis, was shorter with
rabeprazole than with omeprazole. Also, during the first week
of treatment, a significantly higher percentage of patients
treated with rabeprazole reported complete relief of symp-
toms and complete relief of nighttime heartburn than in the
group treated with omeprazole.
This finding has several implications for the management
of GORD. During the few last years, the role of endoscopy in
staging of disease and tailoring of therapy has progressively
been reduced [23]. However, modern treatment of GORD,
based on potent, safe acid inhibition with PPIs, is “symptom-
driven”; the main goal of treatment is the complete relief of
symptoms and the restoration of a normal HRQoL, rather
than the endoscopically verified complete disappearance of
mucosal damage, if present [24]. Even more symptom-driven
nowadays is maintenance treatment, largely based on PPI
“on-demand” therapy [25], i.e., courses of treatment which
can be started and stopped by the patient him/herself accord-
ing to episodic bursts of symptoms. In this respect, an ideal
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in terms of number needed to treat (NNT), the superiority
of rabeprazole in our study could be better appreciated by
considering that the NNT of rabeprazole versus omeprazole
in inducing complete daytime and nighttime heartburn relief
is 7.5, which is extremely good.
As far as maintenance therapy is concerned, the evidence
on the effects of rabeprazole at the time we started the study
was preliminary; a study was published on this issue, suggest-
ing the equivalence of 10 and 20 mg once daily in preventing
relapse of erosive or ulcerative GORD [32]. Immediately
after the publication of this paper, a second study appeared
showing the equivalence of rabeprazole 10 mg daily and
omeprazole 20 mg daily, when administered for 12 months,
in tolerability and in preventing relapse of healed reflux
oesophagitis [33]. In this study, the relapse rates were 5 and
4%, respectively, at week 52.
In our study, overall endoscopic and/or clinical relapse
was evident in 15.2% of patients after an average 11.1 months
of treatment with rabeprazole in the open-label maintenance
phase with low dose of the compound, namely 10 mg once
daily. This rate is lower than that observed in the study by
Birbara et al. [32], i.e., 23% at week 52, and slightly higher
than in the study by Thjodleifsson et al. [33].
In conclusion, we have shown, in a large randomised,
double-blind, controlled clinical trial, the equivalence of
equiponderal doses of rabeprazole and omeprazole in induc-
i
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6PI drug should on one hand achieve an effective control
f intragastric, and hence intra-oesophageal pH, since the
egree of acid suppression in patients with GORD has been
hown to correlate with relief of symptoms and healing rates
f oesophagitis [26,27]. On the other hand, it should also
rovide fast, sustained relief of reflux symptoms as early as
ossible, since this reinforces the correctness of diagnosis as
ell as the patient–doctor relationship, and restores quality
f life and general well-being.
Due to the different pharmacokinetic characteristics of the
ifferent PPIs available, these agents may differ in their onset
f symptom relief. This characteristic is, therefore, currently
onsidered of the utmost clinical importance and several stud-
es describing it have appeared in the literature [28,29].
Rabeprazole has shown to provide more rapid and greater
cid control than lansoprazole, pantoprazole and omepra-
ole [17,30], and possibly also than esomeprazole, the
-chiral isomer of omeprazole recently marketed, when
sed at “equiponderal” doses, i.e., 20 mg versus 20 mg
31].
We believe that, from a clinical point of view, a valuable
eature of our study lies in the measurement of the percent-
ges of patients who were completely heartburn-free (i.e.,
ho did not report a single episode of heartburn during the
reatment period). Using this rigorous outcome parameter,
ur findings confirm that rabeprazole not only provides a
igher percentage of patients with complete relief of symp-
oms already during the first 3 days of treatment, but also that
t maintains its significantly higher efficacy as compared to
meprazole throughout the first week of therapy. Expressedng acute healing of reflux oesophagitis. The former drug
ppears to allow a faster and more sustained onset of action
n symptom relief and is safe and effective in maintaining
bsence of oesophagitis and reflux symptoms when used low-
ose. In our study, within 1 year after acute healing the relapse
ate with rabeprazole 10 mg daily was 15.2% which is lower
han would have been expected from previous studies of sim-
lar disease.
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